Your browser is no longer supported. Please, upgrade your browser.
HOOK HOOKIPA Pharma Inc. daily Stock Chart
HOOKIPA Pharma Inc.
Index- P/E- EPS (ttm)-22.38 Insider Own0.90% Shs Outstand26.02M Perf Week13.57%
Market Cap193.85M Forward P/E- EPS next Y-1.92 Insider Trans- Shs Float14.57M Perf Month-22.96%
Income- PEG- EPS next Q-0.51 Inst Own35.50% Short Float0.29% Perf Quarter-
Sales9.86M P/S19.65 EPS this Y-27.60% Inst Trans454.75% Short Ratio0.29 Perf Half Y-
Book/sh-69.60 P/B- EPS next Y12.70% ROA- Target Price21.00 Perf Year-
Cash/sh2.71 P/C2.75 EPS next 5Y-9.70% ROE- 52W Range6.06 - 14.76 Perf YTD-46.79%
Dividend- P/FCF- EPS past 5Y- ROI37.90% 52W High-52.98% Beta-
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin- 52W Low14.52% ATR0.91
Employees60 Current Ratio5.60 Sales Q/Q- Oper. Margin- RSI (14)41.60 Volatility9.61% 11.20%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume3.51 Prev Close7.45
ShortableNo LT Debt/Eq- EarningsAug 19 AMC Payout- Avg Volume146.15K Price6.94
Recom1.20 SMA20-1.44% SMA50-24.57% SMA200-30.57% Volume79,484 Change-6.85%
May-13-19Initiated RBC Capital Mkts Outperform $23
May-13-19Initiated BofA/Merrill Buy $17
Jul-12-19 07:58AM  Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails Investor's Business Daily +22.90%
07:24AM  The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study Benzinga
Jul-11-19 04:37PM  Hookipa Pharma jumps 40% after FDA approval of clinical tests MarketWatch
04:01PM  HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers GlobeNewswire
02:05PM  [video]Hookipa Soars on FDA OK of Early Stage Trial For Cancer Treatment
Jun-10-19 09:10AM  CEO of Agrios Global Holdings Ltd. Presenting at The Advantage Strategy and Financial Conference June 14, 2019, in Vienna, Austria CNW Group +7.28%
May-20-19 04:01PM  HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
May-08-19 03:47AM  HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead GlobeNewswire
Apr-25-19 08:30AM  HOOKIPA Appoints David R. Kaufman to its Board of Directors GlobeNewswire
Apr-18-19 11:01AM  Hookipa Pharma shares off to lackluster start in trading debut MarketWatch
07:26AM  5 things to know about Hookipa Pharma ahead of its IPO MarketWatch
Apr-17-19 10:49PM  HOOKIPA Pharma Announces Pricing of Initial Public Offering GlobeNewswire
Apr-14-19 09:53AM  IPO Outlook For The Week: Pinterest, Zoom, Biotechs, Minerals And Catastrophe Insurance Benzinga
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.